The brain busting side-effects of Ozempic-like fat jabs revealed – ‘slashing risk of silent killers'
WEIGH TO GO The brain busting side-effects of Ozempic-like fat jabs revealed – 'slashing risk of silent killers'
THEY'VE been hailed as miracle weight-loss jabs - but the effects of Ozempic-style drugs could go far beyond the waistline.
New research suggests these so-called 'skinny pens' may also supercharge your brain and protect against two killer diseases.
3
Fat jabs could keep your brain healthy, experts says
Credit: Getty
3
The popular medicines could reduce the risk of demenita and stroke
Credit: Getty
Scientists from Taiwan found that these fat-busting jabs may help lower the chances of developing dementia and stroke.
People with type 2 diabetes and obesity who took the drugs were also less likely to die early, the researchers discovered.
While everyone knows these drugs, like Wegovy and Mounjaro, help with weight and blood sugar control, experts say some of their other benefits are still a bit of a mystery.
For the study, published in JAMA Network Open, experts from Chang Gung Memorial Hospital looked at data from 60,000 people around the world.
The average age was 58 and all had type 2 diabetes and obesity.
About half of the group were given drugs called GLP1-RAs. These include semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro) to manage their diabetes.
Semaglutide is also the main ingredient in the popular diabetes drug Ozempic, which is licensed for diabetes, while Wegovy is licensed for weight loss.
These drugs work by lowering appetite, slowing digestion, reducing sugar production in the liver, and helping the body make more insulin when needed.
The other half of the participants were on different diabetes medications.
After following everyone for seven years, the researchers found the people using GLP1-RAs had a 37 percent lower risk of dementia and were 19 percent less likely to have a stroke.
Weight Loss Jabs - Pros vs Cons
These conditions are often called silent killers because they can creep up without obvious symptoms until it's too late.
The experts also found those on the drugs were 30 per cent less likely to die during the study period.
The team saw even bigger benefits in people over 60, women, and those with a body mass index between 30 and 40.
There was no difference in the chances of Parkinson's disease or brain bleeds between the groups.
The academics said their findings suggest "potential neuroprotective and cerebrovascular benefits" of the drugs but they called for more studies to confirm the research.
3
Wegovy and Mounjaro are already hailed as wonder drugs for blood sugar control and dramatic weight los
Credit: Alamy
"These findings suggest that semaglutide and tirzepatide may offer neuroprotective and cerebrovascular benefits beyond glycemic control, potentially improving long-term cognitive and survival outcomes in adults with type 2 diabetes and obesity," they wrote.
Commenting on the study, Professor Tara Spires-Jones, from the University of Edinburgh, said: "This is a very interesting study adding to evidence that GLP1 receptor agonists are associated with a lower risk of dementia in people with type 2 diabetes and obesity.
"This type of study cannot determine whether the drugs reduced disease risk by directly protecting the brain.
"It is highly likely that effectively treating type 2 diabetes and obesity would reduce dementia and stroke risk as they are known risk factors for these conditions.
"Further work is needed including randomised clinical trials to confirm these drugs are protective in people with diabetes and obesity and other trials are needed to determine whether these drugs will be protective in people who do not have type 2 diabetes and obesity."
'This is a really exciting '
Dr Richard Oakley, from the Alzheimer's Society, said: "It is well established that diabetes and obesity can increase your risk of developing dementia.
"This study supports existing evidence that shows these drugs may reduce dementia risk, particularly for people aged 60 and over who are living with type 2 diabetes and obesity.
"Although interesting, we can't draw conclusions from this study alone as it is an observational study, only a small number of people who took part went on to develop dementia and as the impact of these drugs on different types of dementia is not clear.
"There are clinical trials currently looking at whether drugs like these can be used to treat early-stage Alzheimer's disease, so this is a really exciting area being explored in the research fight against dementia."
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Scottish Sun
an hour ago
- Scottish Sun
Urgent ‘do not swim' warning to Scots at two popular seaside spots
The warning is in place until further notice STAY AWAY Urgent 'do not swim' warning to Scots at two popular seaside spots Click to share on X/Twitter (Opens in new window) Click to share on Facebook (Opens in new window) AN URGENT "do not swim" warning has been issued to Scots heading to two popular beaches this week. Swimmers looking to take to the water at two beaches in Fife have been urged to stay away due to an ongoing contamination incident. Sign up for Scottish Sun newsletter Sign up 2 The water at Butntisland Beach has high levels of microbiological contamination Credit: Alamy Visitors have been told they should not enter the sea at both Burntisland Beach and Kinghorn Harbour. Both beauty spots overlook the Firth of Forth, with the former being popular for its rock pools and large sandy area, while the latter is located next to a busy caravan park. The Scottish Environment Protection Agency (SEPA) launched an investigation into the incident this week. The alarm was raised after the public body discovered high levels of microbiological contamination after taking readings from the water. This was then shared with Fife Council and the Fife Coast and Countryside Trust. And it prompted the advice to stay clear of the water amid fears that the pollution in the water could lead to illness. Members of the public are temporarily advised against bathing, paddling, or playing in the sea or streams running into both beaches until further notice Fife Coast and Countryside Trus Signs have been erected at key access points at both beaches to highlight the issue. It urges visitors not to swim or paddle in the seas or streams that run into both beaches until further notice. The public has also been warned to keep pets away from the water and wash their hands and shoes if they decide to visit either beach. People have also been urged not to take home anything from the beach, including shells and rocks, and not to gather or eat any shellfish from the area. Man airlifted to hospital after campervan EXPLODES in 'gas blast' at Scots beach Fife Coast and Countryside Trust also shared a warning on social media, asking people to avoid the water. The post on Facebook read: "SEPA has requested members of the public are informed of high Microbiological Contamination readings at Burntisland and Kinghorn Harbour Beaches. "Pollution has been identified by SEPA at Burntisland and Kinghorn Harbour Beaches and exposure may cause illness. "Therefore, members of the public are temporarily advised against bathing, paddling, or playing in the sea or streams running into both beaches until further notice. "Signage has been placed at key access points with the following guidance: Do not enter the water to paddle or swim Keep pets away from the water Wash hands and footwear after visiting the area, and ensure you wash your hands before eating and/or drinking You should not take anything home from the beach You should not gather and/or consume shellfish collected from this area. "For further information please contact SEPA on 03000 99 66 99." Users quickly flocked to the comments of the post to share their concerns after hearing the news. Responding to pollution incidents SEPA has issued the following advice to anyone looking to report pollution incidents. The public body said: "Although rare, pollution incidents affecting bathing water quality can happen. "Pollution incidents tend to be unpredictable, for example, a slurry spill or sewage network failure, and can result in elevated levels of faecal indicators. "To report a possible pollution incident, please use our 24-hour pollution hotline (0800 807060). "In response, we will investigate the incident and contact other relevant organisations. That may include Scottish Ministers, Scottish Water, the local authority and the relevant health board. "Where necessar,y measures will be put in place to resolve the problem. "Whenever our routine sampling of bathing waters identifies elevated levels of faecal indicators, there is an immediate response to check all relevant potential sources and major discharges in the immediate catchment, as well as our hydrometric information to determine whether the levels may be due to high river flows. "Follow-up microbiology sampling is also undertaken of the bathing water and local water courses. "If beach users or bathers are considered to be at risk the local authority will warn the public by erecting signs at the bathing water. Information will also be available on our website. "Other pollutants at the beach may include plastics and litter. Beach users are encouraged to use the bins provided or to take litter home". One person said: "That doesn't sound good, hope they get it sorted soon". Another added: "Be careful with dogs!" Someone else wrote: "I hope all the swimmers are ok as both beaches were mobbed last weekend". While a fourth shared: "Oh no! That's awful." And a fifth chimed in: "Don't come to the beach just now". Fife Council told the Scottish Sun that it has worked with Fife Coast and Countryside Trust to share information on this issue and confirmed that signage is in place at both locations.
Daily Mail
2 hours ago
- Daily Mail
The unexpected Ozempic side effect that has men rushing to get their hands on weight-loss drug
A new study suggests that drugs like Ozempic may do more than lower blood sugar and aid in weight loss - they could also raise testosterone levels in men. Researchers from Saint Louis University Hospital found that men taking GLP-1 medications, including semaglutide (Ozempic) and tirzepatide (Mounjaro), saw their testosterone levels increase by 24 per cent after 18 months of treatment. Testosterone is a vital hormone responsible for male sexual development, muscle mass, bone density, red blood cell production, and fat distribution. Low testosterone is common in men with obesity or Type 2 diabetes and is linked to fatigue, reduced libido, and decreased quality of life. The new findings suggest that GLP-1 drugs may also improve reproductive health in men affected by these conditions. Researchers say the results open the door for further investigation into how anti-obesity medications can impact hormone levels and overall well-being. Lead author Dr Shellsea Portillo Canales, an endocrinology fellow at SSM Health St Louis University Hospital said: 'While it is well known that weight loss from lifestyle changes or bariatric surgery increases testosterone levels, the impact that anti-obesity medications may also have on these levels has not been widely studied. 'Our study is among the first to provide compelling evidence that low testosterone can be reversed with the use of commonly prescribed anti-obesity medications.' The researchers analyzed existing medical records of 110 adult men with obesity or Type 2 diabetes. All of the participants were being treated with semaglutide (Ozempic or Wegovy), dulaglutide (Trulicity) or tirzepatide (Zepbound) for one and a half years. All three drugs are known to mimic the effects of GLP-1, a natural hormone in the body that regulates blood sugar and appetite, often leading to lower blood sugar and weight loss. None of the men were on testosterone or hormonal therapy before or during the experiment. Some risks of testosterone therapy include worsening sleep apnea, acne, enlarging the prostate or breasts, increasing the growth of prostate cancer, reducing sperm counts, causing the testicles to shrink and increasing the risk of clots, according to the Mayo Clinic. The researchers measured the participants' total and free testosterone levels before and during their treatment. Results showed that the participants experienced 10 per cent of weight loss and saw their testosterone levels rise from 53 per cent to 77 per cent. The scientists are yet to discover how GLP-1 drugs can increase testosterone. However, previous research has shown that excess fat can force the body to convert testosterone into estrogen, a female hormone. But when obese individuals start to lose weight, they reduce their body fat stores, which can improve insulin sensitivity in the body and reduce overall inflammation. Both decreased inflammation and weight loss can help the body produce more testosterone and prevent the conversion of the male hormone into estrogen. Talking about the preliminary results, Dr Portillo Canales said: 'Results from this study show that there is a direct correlation between the use of anti-obesity medications and testosterone levels. 'Doctors and their patients can now consider this class of medications not only for the treatment of obesity and to control blood sugar, but also to benefit men's reproductive health.' But despite clear results, the study authors noted that further research is needed to establish a clear link between the drugs and an increase in testosterone. However, seeing how beneficial the discovery is, Dr Fatima Cody Stanford, an obesity medicine physician scientist at Massachusetts General Hospital who was not involved in the study, told NBC News: 'The findings from this study highlight an important intersection between metabolic health and hormonal balance. 'This dual benefit underscores the potential of these medications to enhance overall health outcomes, including reproductive health, in this population.' Average testosterone levels in men are between 300 to 1,000 nanograms per deciliter. Testosterone tends to decline gradually with age, starting around the late 30s to early 40s. By the age of 75, the average male testosterone level drops to about 65 per cent of the average level seen in young adults, Dr Portillo Canales said. The findings were presented today at ENDO 2025, the Endocrine Society's meeting in San Francisco.
Reuters
2 hours ago
- Reuters
As weight-loss spending soars, US employers plan to pare health benefits
NEW YORK, July 16 (Reuters) - More than half of large U.S. employers plan to scale back healthcare benefits next year as rising costs from weight-loss and specialty drugs squeeze budgets, according to a new survey released by consulting firm Mercer on Wednesday. Among employers with 500 or more workers, 51% said they planned to increase cost-sharing in 2026, including raising deductibles and maximum out-of-pocket costs for workers. That is up from 45% of large employers who said they would increase cost-sharing for 2025. Concern over the cost of GLP-1 weight-loss drugs like Novo Nordisk's ( opens new tab Wegovy has surged, with 77% of employers naming them a top issue, the consultancy said. "More clients are saying ... 'I don't know how much longer we can sustain covering these medications'," said Alysha Fluno, a pharmacy innovation leader at Mercer, in an interview. While some employers have covered GLP-1s hoping for long-term health savings, rising prices are forcing a rethink: "Some employers facing big cost increases in 2026 may feel this coverage is out of reach," Fluno said. Greater competition in the weight-loss drug market in coming years will give pharmacy benefit managers more negotiating power with drugmakers and drive meaningful cost reductions, said Fluno. Novo's Wegovy and Eli Lilly's (LLY.N), opens new tab Zepbound are listed at $1086 and $1059, respectively, but many patients pay less through their health plans. Prescription drug costs jumped 8% last year, according to the survey. Mercer has forecast a 5.8% rise in overall health benefit costs for 2025. Employers are also eyeing alternatives to traditional pharmacy benefit managers (PBMs), according to Mercer. PBMs such as CVS Caremark, Cigna's Express Scripts and UnitedHealthcare's Optum Rx act as middlemen between drug companies and consumers. They negotiate volume discounts and fees with drug manufacturers on behalf of employers and health plans, create lists of medications that are covered by insurance, and reimburse pharmacies for prescriptions. Drugmakers say they take an undisclosed cut of the discounts they receive rather than sharing them with patients and payers. Regulatory scrutiny and calls for transparency are fueling interest in new models and emerging PBMs, with 34% of employers considering a switch. The survey found 40% of employers are considering alternative contracting models for their prescription medicine benefits, such as those that price drugs based on the wholesale price that retail pharmacies pay for them. Regulators have criticized the three largest pharmacy benefit managers for steering patients toward more expensive drugs and inflating prices to generate revenue gains, an accusation that the industry denies. California pension fund CalPERS, the second-largest public purchaser of health benefits in the U.S., announced on Tuesday that Caremark would replace UnitedHealth's Optum Rx as the fund's PBM in 2026. CalPERS said its five-year contract with Caremark requires the PBM to boost transparency and oversight.
